In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status.
Where this comes from
- Record sourced from PubMed, PMID 36191324.
- Also identified by DOI 10.7326/J22-0075.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Filippatos G, Butler J, Farmakis D, et al. <b>Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes.</b> Circulation. 2022;146:676-86. 35762322.
Medical subject headings
- Diabetes Mellitus
- Heart Failure